Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Portal hypertension is a lethal complication of cirrhosis. Its mechanism and therapeutic targets remain largely unknown. Hepatic stellate cell (HSC) contraction increases intrahepatic vascular resistance contributing to portal hypertension. We investigated how HSC contraction was regulated by Wnt signaling and the therapeutic implication.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>Liver tissues from cirrhotic patients were examined. Cirrhotic mice with genetic or pharmacological treatments were used for <i>in vivo</i> assessments and their primary cells were isolated. Cellular functions and signaling pathways were analyzed in human HSC‐LX2 cells using real‐time PCR, Western blotting, siRNA, luciferase reporter assay, chromatin immunoprecipitation, co‐immunoprecipitation, and site‐directed mutagenesis. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>Wnt/β‐catenin correlated with HSC contraction in human cirrhotic liver. Wnt3a stimulated Smo‐independent Gli1 nuclear translocation followed by LARG‐mediated RhoA activation leading to HSC contraction. Sufu negatively mediated Wnt3a‐induced Gli1 nuclear translocation. Wnt/β‐catenin repressed the transcription of Sufu dependent on β‐catenin/TCF4 interaction and TCF4 binding to Sufu promoter. Molecular simulation and site‐directed mutagenesis identified the β‐catenin residues Lys312 and Lys435 critically involved in the interaction. Additionally, TCF4 binding to the sequence CACACCTTCC at Sufu promoter was required for transrepression of Sufu. In cirrhotic mice, short‐term liver‐targeting β‐catenin deficiency or acute treatment with β‐catenin inhibitors reduced portal pressure via restriction of HSC contraction rather than inhibition of HSC activation. Long‐term deficiency or treatments also ameliorated liver injury, fibrosis and inflammation.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions and Implications</h3><p>Interaction between Wnt/β‐catenin and Smo‐independent Gli1 pathways promoted HSC contraction via TCF4‐dependent transrepression of Sufu. HSC‐specific inhibition of β‐catenin may have therapeutic benefits for cirrhotic portal hypertension.</p></section>

CAT1 Silencing Inhibits TGF-β1-induced Mouse Hepatic Stellate Cell Activation in Vitro and Hepatic Fibrosis in Vivo.

Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling

[Effect of Beta-Catenin on the Activation of Hepatic Stellate Cells Induced by Transforming Growth Factor-Beta1].

Transforming Growth Factor-1 Downregulation of Smad 1 Gene Expression in Rat Hepatic Stellate Cells

β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation.

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

Treatment of Cholestatic Fibrosis by Altering Gene Expression of Cthrc1: Implications for Autoimmune and Non-Autoimmune Liver Disease

Catalpol Inhibits Hepatic Stellate Cell Activation by Reducing the Formation and Changing the Contents of Hepatocyte-Derived Extracellular Vesicles

TGF-β1 Signaling Regulates Mouse Hepatic Stellate Cell Differentiation Via the Jagged1/Notch Pathway.

RNA interfering connective tissue growth factor prevents rat hepatic stellate cell activation and extracellular matrix production.

TGF-β1 activates mouse hepatic stellate cells through Jagged1/Notch

CXCL6-EGFR-induced Kupffer Cells Secrete TGF-beta 1 Promoting Hepatic Stellate Cell Activation Via the SMAD2/BRD4/C-MYC/EZH2 Pathway in Liver Fibrosis

TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation

Macrophage-derived cathepsin S remodels the extracellular matrix to promote liver fibrogenesis

Cathepsin H-Mediated Degradation of HDAC4 for Matrix Metalloproteinase Expression in Hepatic Stellate Cells: Implications of Epigenetic Suppression of Matrix Metalloproteinases in Fibrosis through Stabilization of Class IIa Histone Deacetylases.

Catalase ameliorates hepatic fibrosis by inhibition of hepatic stellate cells activation

Regulation of hepatic stellate cell contraction and cirrhotic portal hypertension by Wnt/β‐catenin signalling via interaction with Gli1

XIAP-mediated degradation of IFT88 disrupts HSC cilia to stimulate HSC activation and liver fibrosis

Igf2bp2 Knockdown Improves CCl4-induced Liver Fibrosis and TGF-β-activated Mouse Hepatic Stellate Cells by Regulating Tgfbr1

Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells.